NIAMS Clinical Study Implementation Cooperative Agreement (UM1) | Apply Online

Opportunity Summary:

The NIAMS Clinical Study Implementation Cooperative Agreement (UM1), Funding Opportunity Number PAR-11-168, is a National Institutes of Health discretionary funding opportunity designed to support the actual conduct and execution of investigator-initiated interventional clinical trials across all phases, as long as the topic falls squarely within the mission area of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The mechanism is a cooperative agreement (UM1), which generally means NIAMS expects to have substantial scientific and/or programmatic involvement during the life of the award rather than operating purely as a hands-off grant. In practical terms, this FOA is aimed at trials that are ready to launch and run, with the major planning work already completed and with clear operational milestones that allow NIAMS to track progress and performance.

A central feature of this program is NIAMS's typical expectation that applicants follow a two-step pathway for clinical trials. First, investigators usually complete a dedicated planning phase under the NIAMS Clinical Trial Planning Cooperative Agreement (U34), referenced as PAR-11-169. That U34 step is meant to ensure critical pre-trial preparation is finished before implementation funding is requested, such as finalizing the protocol, defining outcomes, building the recruitment and retention plan, establishing data and safety monitoring, preparing manuals of procedures, and putting the operational infrastructure in place. After that planning phase is complete, the same team would then submit for the UM1 implementation phase (Part 2) to carry out the trial. At the same time, the FOA makes clear that the U34 is not the only path: investigators who have already completed all necessary pre-trial planning and preparation through other means may apply directly for the UM1, as long as they can demonstrate they are truly implementation-ready.

NIAMS emphasizes that the clinical trials it supports through this UM1 should be hypothesis-driven and milestone-defined. "Hypothesis-driven" signals that the study should be anchored to a clear scientific question with a rationale, pre-specified endpoints, and an analysis plan capable of producing interpretable results, rather than being primarily exploratory or infrastructure-building. "Milestone-defined" implies that the project should be structured around measurable deliverables such as site activation timelines, enrollment targets, follow-up completion rates, data quality metrics, and adherence to safety monitoring and reporting requirements. NIAMS also notes that funded trials should be related to its research mission in arthritis, musculoskeletal diseases, and skin diseases and should be considered high priority by the Institute, which points to the importance of demonstrating both scientific significance and alignment with NIAMS programmatic needs.

Another key expectation is early communication with the Institute. The announcement strongly encourages applicants to consult with NIAMS staff before submitting a UM1 application. This kind of pre-application discussion is often used to confirm mission fit, clarify whether a UM1 is the right mechanism, discuss readiness for implementation, and surface any design, feasibility, or regulatory considerations that could affect review or award decisions. For a cooperative agreement in particular, these conversations can help applicants understand how NIAMS may engage during trial execution and what reporting, milestone, and governance structures the Institute may expect.

In terms of eligibility, the opportunity is broad within the United States and its territories. Eligible applicants include many types of domestic organizations such as public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), small businesses, for-profit organizations (including those other than small businesses), and a wide range of government entities such as state, county, city/township, special district governments, independent school districts, and public housing/Indian housing authorities. The FOA also explicitly includes various mission-focused and community-centered institution types and organizations, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, tribally controlled colleges and universities (TCCUs), faith-based or community-based organizations, regional organizations, and eligible federal agencies. Foreign organizations (non-U.S. entities) are not eligible to apply, although foreign components of U.S. organizations are allowed, which commonly means a U.S. applicant can include an overseas site or collaboration if it is justified and compliant, but the applicant organization itself must be domestic.

Administratively, the FOA is listed under the NIH with the CFDA number 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research). It does not require cost sharing or matching. The opportunity was posted and created on March 18, 2011, with an original and current closing date of March 1, 2014, and an archive date of April 1, 2014, indicating it is no longer active in its original form but remains as a record of the funding mechanism and requirements at the time. The full announcement was hosted through the NIH Grants Guide (linked in the source data), and NIH Office of Extramural Research (OER) webmaster contact information is provided for access or linking issues.

Overall, this UM1 FOA is best understood as NIAMS support for the implementation stage of a rigorously planned, priority-aligned interventional clinical trial, with strong emphasis on readiness, operational milestones, and active coordination with NIAMS staff typical of a cooperative agreement award.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: NIAMS Multi Center Clinical Study Implementation Planning Grants (U34)

Previous opportunity: Improving Surveillance for Diseases of Public Health Significance for U.S. Bound Refugees and Other Mobile Populations Thailand

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 11 168

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 11 168) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 168", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.